指南与共识复苏、休克与脓毒症重症综合管理与镇静镇痛

国际共识推荐聚焦更新:重症成人患者延长输注β-内酰胺类抗生素

Focused Update to International Consensus Recommendations for the Use of Prolonged-Infusion Beta-Lactam Antibiotics Among Severely Ill Adult Patients: Endorsed by the American College of Clinical Pharmacy, British Society for Antimicrobial Chemotherapy, Cystic Fibrosis Foundation, European Society of Clinical Microbiology and Infectious Diseases, Infectious Diseases Society of America, Society of
指南 / 共识 · Pharmacotherapy · 2026-01-01
一句话结论国际共识聚焦更新推荐:重症成人患者使用延长输注β-内酰胺类抗生素以改善生存和临床治愈,并在持续输注前使用负荷剂量(建议)。

该聚焦更新基于28项评估死亡率的随机对照试验(RCT)和21项评估临床治愈的RCT,重新评价延长输注对比短时间输注β-内酰胺类抗生素在重症成人患者中的疗效。汇总分析显示延长输注降低死亡率(RR 0.91;95%CI 0.85至0.97),贝叶斯分析显示获益后验概率98.76%;临床治愈改善(RR 1.11;95%CI 1.06至1.17),后验概率99.97%。证据确定性较原始推荐提升:死亡率为中等,临床治愈为低。亚组分析提示持续输注前使用负荷剂量可改善结局,建议启动持续输注时继续使用负荷剂量。

要点

  • 在重症成人患者中,延长输注β-内酰胺类抗生素较短时间输注降低死亡率(RR 0.91;95%CI 0.85至0.97)。
  • 延长输注改善临床治愈(RR 1.11;95%CI 1.06至1.17)。
  • 证据确定性:死亡率为中等,临床治愈为低。
  • 亚组分析提示持续输注前使用负荷剂量可改善结局,建议启动持续输注时使用负荷剂量。
  • 未来研究应识别最可能获益的亚人群、明确最佳延长输注策略及治疗药物监测的作用。

适用人群与场景

  • 重症成人患者。

处置流程与药物剂量

  • 推荐在重症成人患者中使用延长输注β-内酰胺类抗生素而非短时间输注,以改善死亡率或临床治愈(原始2023年国际共识建议,证据确定性极低;本次更新后死亡率证据确定性为中等、临床治愈为低)。
  • 建议在启动持续输注治疗时使用负荷剂量(与原始推荐PICO X一致,亚组分析提示使用负荷剂量可改善结局)。

研究设计与关键结果

  • 研究类型:国际共识聚焦更新,纳入28项评估死亡率的RCT和21项评估临床治愈的RCT,采用贝叶斯Meta分析。
  • 死亡率:延长输注组较短时间输注组降低(RR 0.91;95%CI 0.85至0.97),贝叶斯分析获益后验概率98.76%。
  • 临床治愈:延长输注组较短时间输注组改善(RR 1.11;95%CI 1.06至1.17),贝叶斯分析获益后验概率99.97%。
  • 证据确定性:死亡率为中等,临床治愈为低。
  • 亚组分析:评估负荷剂量的亚组分析提示持续输注前使用负荷剂量可改善结局。

证据类型、等级与局限

  • 证据类型:国际共识指南聚焦更新,基于RCT的Meta分析(含贝叶斯Meta分析)。
  • 证据等级:死亡率证据确定性为中等,临床治愈证据确定性为低。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对重症成人患者,脓毒症或脓毒性休克等危重情况下使用β-内酰胺类抗生素时,可改变做法为选择延长输注而非短时间输注,以改善生存和临床治愈。
  • 启动持续输注时,建议给予负荷剂量。
  • 未来研究需识别最可能获益的亚人群、明确最佳延长输注策略及治疗药物监测的作用。

指南或共识出处

  • 国际共识推荐聚焦更新:重症成人患者延长输注β-内酰胺类抗生素的使用,得到美国临床药学学院、英国抗微生物化疗学会、囊性纤维化基金会、欧洲临床微生物学和感染性疾病学会、美国感染病学会等认可。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

In 2023, international consensus recommendations suggested the use of prolonged-infusion beta-lactam antibiotics over short-infusion dosing in severely ill adult patients to improve mortality or clinical cure, although the certainty of evidence was very low. With the availability of several new randomized controlled trials (RCTs), this focused update re-evaluates the efficacy of prolonged versus short infusion among severely ill adult patients. The original Population, Intervention, Comparator, and Outcome (PICO) question VII was separated into two questions addressing mortality (VIIa) and clinical cure (VIIb). Methods used for study identification, screening, and evidence grading were consistent with the original guideline, with the addition of Bayesian meta-analyses. A total of 28 RCTs evaluating mortality in severely ill adults were analyzed, with pooled estimates favoring prolonged infusion (RR 0.91; 95% confidence interval 0.85 to 0.97), supported by Bayesian analyses demonstrating a 98.76% posterior probability of benefit. Across 21 RCTs evaluating clinical cure, prolonged infusion improved outcomes compared with short infusion (RR 1.11; 95% confidence interval 1.06 to 1.17), supported by Bayesian analyses demonstrating a 99.97% posterior probability of benefit. Certainty of evidence was strengthened to moderate for mortality and low for clinical cure. Consistent with the original recommendation (PICO X), subgroup analyses evaluating loading doses suggested improved outcomes when a loading dose is used before continuous infusion. Overall, the cumulative evidence reinforces and strengthens the recommendation for use of prolonged-infusion beta-lactam therapy in severely ill adult patients to improve survival and clinical cure. Continued use of loading doses when initiating continuous-infusion therapy is suggested. Future research should identify subpopulations most likely to benefit, clarify optimal prolonged-infusion strategies, and define the role of therapeutic drug monitoring.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

参考来源

  1. Hong LT, FakhriRavari A, Ulldemolins M, et al. Focused Update to International Consensus Recommendations for the Use of Prolonged-Infusion Beta-Lactam Antibiotics Among Severely Ill Adult Patients: Endorsed by the American College of Clinical Pharmacy, British Society for Antimicrobial Chemotherapy, Cystic Fibrosis Foundation, European Society of Clinical Microbiology and Infectious Diseases, Infectious Diseases Society of America, Society of Critical Care Medicine, and Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2026. PMID: 42598847. doi:10.1002/phar.70188

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。